Tag: Xience
First patient enrolled in trial reviewing 28-day DAPT with Xience
The first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet ...
ESC 2017: Significantly lower event rates with Orsiro than with Xience
Results from the BIOFLOW V study indicate that patients who undergo percutaneous coron...
New study to evaluate safety of three-month DAPT with Xience in high bleeding risk patients
A new study, XIENCE Short DAPT, will evaluate whether three months of dual antiplatelet therapy ...
TCT 2016: Three-year data fail to show Absorb to be superior or even non-inferior to Xience
According to the three-year results of the ABSORB II trial, a bioresorbable vascular scaffold (A...
